January 24, 2020 06:17 AM ESTUpdated 06:42 AM

Roche's checkpoint player Tecentriq flops in another bladder cancer subset

Natalie Grover

Reporter

Just weeks after Merck’s star checkpoint inhibitor Keytruda secured FDA approval for a subset of bladder cancer patients, Swiss competitor Roche’s Tecentriq has failed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roche's checkpoint player Tecentriq flops in another bladder cancer subset

Natalie Grover

Reporter

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Biotech seed rounds sink to lowest level in years as industry slump drags on

US drugs rely heavily on ingredients made overseas, new report shows

Pharma's wins and losses in Trump's sprawling executive order on drug prices

Trump pledges his support for a change to the IRA long sought by drugmakers

Sarepta loses CMO to RNA editing upstart; Another wave of personnel moves at Dyne

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

Roche's check­point play­er Tecen­triq flops in an­oth­er blad­der can­cer sub­set

Reporter

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

Roche's checkpoint player Tecentriq flops in another bladder cancer subset